Imaging Biomarkers for Myofascial Pain
Launched by GEORGE MASON UNIVERSITY · Sep 27, 2023
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Definition of proposed composite multimodal biomarker-The investigators propose to develop a quantitative tissue-level classifier based on quantitative metrics (features) derived from ultrasound elastography, Doppler, bioimpedance spectroscopy and high-density electromyography, as an indicator of the normal biological process in myofascial tissues, and pathogenic process in active and latent phases of myofascial pain.
Overall approach and scientific rigor: In Aim 1, the investigators will develop methods to generate reproducible metrics (features) from the raw tissue-level measures and det...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and older
- Exclusion Criteria:
- • Diagnosis of fibromyalgia, chronic fatigue syndrome or chronic Lyme disease confirmed by physical exam
- • Diagnosis of cervical radiculopathy, neuropathy or neuriitis
- • History of head, neck, or shoulder girdle surgery
- • Atypical facial neuralgia
- • New medication or change in medication in past 6 months
- • Current throat or ear infection
About George Mason University
George Mason University, a prominent public research institution located in Fairfax, Virginia, is dedicated to advancing knowledge and improving health outcomes through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, the university conducts a wide range of clinical trials aimed at addressing pressing health challenges and enhancing patient care. Leveraging its diverse faculty expertise and state-of-the-art facilities, George Mason University fosters a dynamic environment for scientific inquiry and discovery, ultimately contributing to the development of effective therapies and interventions that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fairfax, Virginia, United States
Patients applied
Trial Officials
Siddhartha Sikdar, PhD
Principal Investigator
George Mason University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported